Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Claire, Telford"'
Autor:
Joseph Biskupiak, Sudhir Unni, Claire Telford, Minkyoung Yoo, Xiangyang Ye, Rishi Deka, Diana Brixner, David Stenehjem
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Breast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health ca
Externí odkaz:
https://doaj.org/article/d94ffe977e5144f598a1a1dd0daf5490
Autor:
Pavel Michálek, Will Donaldson, Francis McAleavey, Alexander Abraham, Rachel J. Mathers, Claire Telford
Publikováno v:
Prague Medical Report, Vol 117, Iss 4, Pp 164-175 (2016)
Fibreoptic intubation through a supraglottic airway is an alternative plan for airway management in difficult or failed laryngoscopy. The aim of this study was to compare three supraglottic airways as conduits in patients with at least one predictor
Externí odkaz:
https://doaj.org/article/6e21ac42b3474548af0af2b73f919a12
Autor:
Jerzy E. Tyczynski, Lia Gutierrez, Rishi Deka, Amy Sainski, Junjie Ma, Tapashi Dalvi, David D. Stenehjem, Casey R. Tak, Marisa B. Schauerhamer, Claire Telford, Joseph Biskupiak, James A. Kaye, Sudhir Unni, Diana I. Brixner, Hillevi Bauer, Xiangyang Ye
Publikováno v:
Breast Cancer Research and Treatment. 186:839-850
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24d9cd4568eaf6f4d1dfff6318c4c3b1
https://doi.org/10.1007/s10549-020-06038-x
https://doi.org/10.1007/s10549-020-06038-x
Autor:
Evelina Bertranou, Mattias Ekman, Christopher Livings, Samuel Large, Claire Telford, Hilary Phelps
Publikováno v:
PharmacoEconomics Open
Introduction The selective estrogen receptor degrader fulvestrant is approved for the first-line treatment of postmenopausal patients with hormone receptor-positive (HR+), locally advanced or metastatic breast cancer who have not received prior endoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd609c8ac08943753b37cb62933e463b
https://doi.org/10.1007/s41669-019-0134-3
https://doi.org/10.1007/s41669-019-0134-3
Publikováno v:
Leukemialymphoma. 62(10)
Acalabrutinib is a highly selective, potent, next-generation, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity. Matching-adjusted indirect comparisons (MAICs) were performed to estimate the safety and efficacy of acalabrutin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd74b8e6266585c6e39f40b55a4c95a2
https://pubmed.ncbi.nlm.nih.gov/33955326
https://pubmed.ncbi.nlm.nih.gov/33955326
Autor:
David D, Stenehjem, Claire, Telford, Sudhir K, Unni, Hillevi, Bauer, Amy, Sainski, Rishi, Deka, Marisa B, Schauerhamer, Xiangyang, Ye, Casey R, Tak, Junjie, Ma, Tapashi B, Dalvi, Lia, Gutierrez, James A, Kaye, Jerzy E, Tyczynski, Diana I, Brixner, Joseph E, Biskupiak
Publikováno v:
Breast cancer research and treatment. 186(3)
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f45000659d91957201e3f7c35934b58
https://pubmed.ncbi.nlm.nih.gov/33389410
https://pubmed.ncbi.nlm.nih.gov/33389410
Autor:
Joseph Biskupiak, Diana I. Brixner, Rishi Deka, David D. Stenehjem, Minkyoung Yoo, Xiangyang Ye, Sudhir Unni, Claire Telford
Publikováno v:
BMC Health Services Research
BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021)
Background Breast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health care and br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5f87dadf625ad7495e5cd9d0bb7bd0
https://pubmed.ncbi.nlm.nih.gov/33435985
https://pubmed.ncbi.nlm.nih.gov/33435985
Publikováno v:
PharmacoEconomics Open
Objectives In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe9d591fabbad54549eb57f6df56c1c
https://doi.org/10.1007/s41669-017-0031-6
https://doi.org/10.1007/s41669-017-0031-6
Autor:
Will Donaldson, Alexander Abraham, Pavel Michalek, Rachel J Mathers, Francis McAleavey, Claire Telford
Publikováno v:
Prague Medical Report, Vol 117, Iss 4, Pp 164-175 (2016)
Fibreoptic intubation through a supraglottic airway is an alternative plan for airway management in difficult or failed laryngoscopy. The aim of this study was to compare three supraglottic airways as conduits in patients with at least one predictor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87aa531187aa48316f00c866cee7a73
https://pmr.lf1.cuni.cz/117/4/0164/
https://pmr.lf1.cuni.cz/117/4/0164/
Autor:
Chantal Avila, Jerzy E. Tyczynski, Lia Gutierrez, Jiaxiao M. Shi, Reina Haque, Tapashi Dalvi, Monica Alvarado, James A. Kaye, Claire Telford, George E. Tiller
Publikováno v:
The Permanente Journal. 22
Context Little information exists on whether breast cancer survival differs by BRCA1 or BRCA2 mutation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b830f4e88c6d763daa55503127f7c9d
https://doi.org/10.7812/tpp/17-197
https://doi.org/10.7812/tpp/17-197